KCNJ2 and short QT syndrome type 3: Furthermore, short QT syndrome type 3, due to an increase in KIR2.1 mediated IK1 (e.g., Hattori et al., 2012) may benefit from such a pharmacological approach also when Golgin-97 has a role in ventricular KIR2.1 trafficking.